VX-222
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Chronic Hepatitis C VirusChronic Hepatitis C Virus Infection
Phase 2
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
TerminatedNCT01080222
Start: 2010-08-31End: 2013-11-30Updated: 2020-09-30
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
CompletedNCT01516918
Start: 2012-02-29End: 2013-12-31Updated: 2014-10-20
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
CompletedNCT01581138
Start: 2012-07-31End: 2013-12-31Updated: 2014-07-04